{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:52:32Z","timestamp":1762865552991,"version":"3.40.4"},"reference-count":11,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Princ Pract"],"published-print":{"date-parts":[[2009]]},"abstract":"<i>Objective:<\/i> The purpose of this study was to determinewhether or not imatinib mesylate therapy induces growth hormone deficiency (GHD). <i>Subjects and Methods:<\/i> Seventeen patients with chronic myloid leukemia (CML) were enrolled in the study. The glucagon stimulation test (GST), and standard deviation scores (SDSs) of insulin-like growth fac- tor 1 (IGF-I) and insulin-like growth factor binding protein (IGFBP-3) were used to determine GHD. The <i>L<\/i>-dopa test was performed on those with IGF-I SDSs above the \u20131.8 cut-off level. <i>Results:<\/i> Of the 17 patients in the study, 12 (70%) had severe GHD (serum GH level <3 \u03bcg\/l after GST). IGF-I SDSs and IGFBP-3 SDSs were below \u20131.8 in 12 patients (70%) and below \u20130.9 in 10 subjects (58%). Four of the 5 remaining subjects with IGF-I SDS >\u20131.8 showed insufficient GH response to <i>L<\/i>-dopa stimulation. Nine subjects (52%) had both severe GHD based on GST response and IGF-I SDS below \u20131.8. If an IGF-I SDS cut-off value l<\u20133 were used,5 out of 17 subjects (30%) would be classified as GH deficient. These same patients also showed severe GHD based on GST response. <i>Conclusions:<\/i> The data showed that a large number of patients on imatinib mesylate therapy had GH deficiency. A study involving a larger number of patients with a matched control group is needed to confirm the present observations.<\/jats:p>","DOI":"10.1159\/000226288","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T11:27:44Z","timestamp":1249039664000},"page":"360-363","source":"Crossref","is-referenced-by-count":20,"title":["Does Imatinib Mesylate Therapy Cause Growth Hormone Deficiency?"],"prefix":"10.1159","volume":"18","author":[{"given":"L.","family":"Kebapcilar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Bilgir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Alacacioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Payzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bilgir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Oner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Calan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Binicier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1124%2Fpr.55.3.4"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.87.5.2067"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.2003-030412"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11102-007-0031-0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11102-007-0028-8"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.onc.1209959"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.2005-2227"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0145-2126%2801%2900011-X"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210%2Fjcem-68-2-469"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2265.2007.03120.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038%2Fnm1446"}],"container-title":["Medical Principles and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/226288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/226288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:03:19Z","timestamp":1745449399000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000226288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000226288","archive":["Portico"],"relation":{},"ISSN":["1011-7571","1423-0151"],"issn-type":[{"type":"print","value":"1011-7571"},{"type":"electronic","value":"1423-0151"}],"subject":[],"published":{"date-parts":[[2009]]}}}